Apellis Pharmaceuticals Inc
APLS
ISIN US03753U1060 / Valor 30132056
Apellis Pharmaceuticals Inc
UMushroom community rating:
About company
Apellis Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery and development of novel therapies to treat a range of debilitating diseases by targeting the complement cascade, a key component of the immune system. The company has pioneered the first new class of complement medicine in over a decade, with two approved treatments that focus on C3, the central protein in the complement cascade. This includes the groundbreaking therapy for geographic atrophy, a major cause of blindness worldwide. Founded by a group of post-doctoral scientists in Kentucky, Apellis has grown on the strength of its innovative scientific approach and commitment to addressing significant unmet medical needs. The company's pipeline includes nearly a dozen clinical and pre-clinical programs aimed at exploiting the therapeutic potential of targeting C3 in various serious diseases.
Summarized from source with an LLMView SourceSector: HealthcareKey figures
Performance
Volatility
3575 M
Market cap (USD)
762,655
Daily traded volume (Shares)
29.03 / 27.73
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
Petros Gakidis
EQUITIES OF THE SAME SECTOR
